Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Neuroblastoma D009447 66 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Nerve Degeneration D009410 53 associated lipids
Parkinson Disease D010300 53 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Peritonitis D010538 38 associated lipids
Lung Diseases D008171 37 associated lipids
Nervous System Diseases D009422 37 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Fever D005334 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Epilepsy D004827 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Burns D002056 34 associated lipids
Acute Lung Injury D055371 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Stroke D020521 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Proteinuria D011507 30 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Neuralgia D009437 28 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Gastritis D005756 27 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Endotoxemia D019446 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Brain Diseases D001927 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Madi S et al. Allergen-induced bronchospasm in passively sensitized guinea pigs: influence of new substances in comparison to reference compounds. 1991 Agents Actions pmid:2058463
Braquet P and Esanu A New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. 1991 Agents Actions pmid:2058466
Northover AM Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. 1990 Agents Actions pmid:2111079
McLeod J et al. Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on substance P-induced histamine release from rat peritoneal mast cells. 1990 Agents Actions pmid:1695435
Trebien HA and Calixto JB Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. 1989 Agents Actions pmid:2660497
Bekemeier H and Sänze JU Vasodepression ex vivo after administration of inflammatory mediators in vivo in the rat. 1989 Agents Actions pmid:2476918
Jouquey S et al. Comparison of the effects of the ace inhibitors trandolapril and enalapril on phlogogen induced foot pad oedema in the rat. 1988 Agents Actions pmid:2459935
Sanchez Crespo M and Nieto ML Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. 1989 Agents Actions pmid:2711927
Zijlstra FJ et al. The effects of PAF-acether and FMLP on eicosanoid production in guinea pig alveolar macrophages. 1989 Agents Actions pmid:2711928
Nijkamp FP et al. Role of platelet activating factor in the endotoxin induced tracheal hyperreactivity to histamine in the guinea pig. 1989 Agents Actions pmid:2711929
Oliver JL et al. Effect of PAF acether on oriented egg phosphatidylcholine multibilayers; interaction with cholesterol; comparison to lyso-PC and lyso-PAF. 1989 Agents Actions pmid:2711930
Nieminen MM et al. Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. 1991 Agents Actions pmid:1862740
Jenei B et al. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). 1991 Agents Actions pmid:1862750
Kantar A et al. Effect of PAF on erythrocyte membrane heterogeneity: a fluorescence study. 1991 Agents Actions pmid:1862752
Swingle KF and Reiter MJ Inhibition of Paf-acether-induced edema of the rat's paw. 1986 Agents Actions pmid:2875631
Flower RJ Background and discovery of lipocortins. 1986 Agents Actions pmid:2938452
Carlson RP et al. Pharmacologic modulation of PAF-induced mortality in mice. 1987 Agents Actions pmid:3120513
Anderson GP et al. Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites. 1988 Agents Actions pmid:3136622
Cunha FQ et al. Failure of PAF-acether to induce in vivo neutrophil migration. 1988 Agents Actions pmid:3055873
Touvay C et al. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. 1986 Agents Actions pmid:3754380
Etienne A et al. In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. 1986 Agents Actions pmid:3515870
Mastacchi R et al. Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets. 1986 Agents Actions pmid:3518359
Kusner EJ et al. Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. 1987 Agents Actions pmid:3577957
Pettipher ER et al. PAF-acether in chronic arthritis. 1987 Agents Actions pmid:3630862
Perales J et al. Neutralization of the oedematogenic activity of Bothrops jararaca venom on the mouse paw by an antibothropic fraction isolated from opossum (Didelphis marsupialis) serum. 1992 Agents Actions pmid:1295374
Wong CW et al. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. 1992 Agents Actions pmid:1414679
Tran A et al. Separate induction of human blood platelet aggregation or cytotoxicity by different concentrations of PAF-acether and thrombin. 1992 Agents Actions pmid:1414687
Okamoto H et al. Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. 1992 Agents Actions pmid:1388318
Miyagawa H et al. The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils. 1992 Agents Actions pmid:1456179
Ogunbiyi PO and Eyre P Pharmacological studies of pulmonary anaphylaxis in vitro: a review. 1985 Agents Actions pmid:2420161
Lewis AJ et al. The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. 1984 Agents Actions pmid:6152379
Benveniste J Platelet-activating factor (PAF-acether): present status. 1981 Agents Actions pmid:6176101
Raff GW et al. Procoagulant property of platelet activating factor (PAF). 1993 Agents Actions pmid:8273543
Meats JE et al. Identification of phospholipase D (PLD) activity in mouse peritoneal macrophages. 1993 Agents Actions pmid:8273553
Thomas TK et al. Differential antagonism of platelet activating factor-induced neutrophilia and gastric hemorrhage in the rat. 1993 Agents Actions pmid:8273566
Glaser KB et al. Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2). 1993 Agents Actions pmid:8273577
Kantar A et al. Effect of PAF on human lymphocyte membranes: a fluorescence study. 1993 Agents Actions pmid:8317302
Boonen GJ et al. Activation of neutrophil migration by dioctanoyl-sn-glycerol and fMet-Leu-Phe is controlled by different pathways. 1993 Agents Actions pmid:8317308
Murphy G Report of the 14th meeting of the British Inflammation Research Association. Topic: cellular and molecular aspects of inflammatory bowel disease. 1993 Agents Actions pmid:8480529
Sakamoto T et al. Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig. 1993 Agents Actions pmid:7908496
Jouvin-Marche E et al. Platelet-activating factor (PAF-acether), an activator of neutrophil functions. 1982 Agents Actions pmid:6299078
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Heller R et al. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. 1993 Agents Actions pmid:7517616
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Czarnetzki BM and Benveniste J Effect of synthetic PAF-acether on human neutrophil function. 1981 Agents Actions pmid:7041568
Camussi G et al. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). 1981 Agents Actions pmid:7041569
de Bernardis E et al. Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. 1994 Agents Actions pmid:7847181
Guinot P et al. Effects of BN 52063 on PAF-acether induced weal and flare in man. 1987 Agents Actions Suppl. pmid:3479000
Lang M et al. Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets. 1987 Agents Actions Suppl. pmid:3479001
Braquet P et al. The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021. 1987 Agents Actions Suppl. pmid:3314418